(beraking latest news) – The press conference entitled ‘Acute Myeloid Leukemia: new perspectives in the management of the disease’ was held in Rome. The event was attended by numerous experts in the sector who were able to illustrate the news regarding an aggressive hematological disease which affects around 3,300 people in Italy every year, most of whom are elderly patients. Among the novelties, it is worth mentioning the green light by AIFA for the reimbursement of the drug Venetoclax in combination with azacitidine for those who are not suitable for standard intensive chemotherapy. The drug extends survival by 15 months.
Acute myeloid leukemia, Aifa approves new innovative therapy